Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
ART and Pediatric Cancer: Risk May Vary by Method Used, Cancer Type Research has suggested that ART may increase the risk of pediatric cancers, but studies have shown conflicting results, and questions remain.
ASH 2022: MCL Trials Break New Ground, May Change Practice Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
ASH 2022: New Findings in CLL Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
ASH 2022: Trials Show Promising Results in Follicular Lymphoma Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.